- News Releases
-
- Oct. 18, 2021 (PDF/247KB)Licensing
- Sumitomo Dainippon Pharma and BehaVR announce landmark deal for multiple virtual reality digital therapeutics
-
- Oct. 11, 2021 (PDF/344KB)Products
- Enzyvant Receives FDA Approval for RETHYMIC (allogeneic processed thymus tissue-agdc), a One-Time Regenerative Tissue-Based Therapy for Pediatric Congenital Athymia
Other Notices
-
- Jun. 30, 2021Others
- Posted Factbook 2021
-
- Jun. 24, 2021Corporate (PDF/103KB)
- Sumitomo Dainippon Pharma Announces Release of Movie on Change of Company Name
IR Library
-
Change company name from April 2022
-
Continuing to challenge ourselves to support a healthy future for people
-
Aiming to create innovative pharmaceutical products
-
Targeting sustainable growth
-
Leading our global expansion
-
Thinking BEYOND medication